Aleafia Health Provides Further Update on its Convertible Debt

Rhea-AI Summary

Aleafia Health has entered into a Forbearance Agreement with holders representing 58% of its total convertible debentures. The agreement, effective until February 28, 2022, allows the company to negotiate better terms for the Convertible Debt, originally issued on June 27, 2019, and maturing this June.

The Holders have agreed to postpone enforcement actions regarding interest non-payment. While negotiations for amending the debt terms are underway, no guarantees exist for a successful outcome.

Positive

• Entered a Forbearance Agreement with 58% of debenture holders, allowing time to negotiate terms.
• Negotiations aim to amend convertible debt terms benefiting all stakeholders.

Negative

• Non-payment of interest could indicate cash flow challenges.
• No assurance that negotiations will be successful, leaving future obligations uncertain.

• Entered into Forbearance Agreement with Holders representing 58% of total Debentures
  
• Negotiating a potential transaction to amend the Convertible Debt terms for all debenture holders

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, AH.DB, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is providing a corporate update regarding its outstanding listed unsecured convertible debentures (TSX: AH.DB), issued on June 27, 2019 and maturing on June 27, 2022 (the “Convertible Debt”).

Further to the Company’s announcement on January 4, 2022, Aleafia Health is advancing towards achieving a beneficial outcome for all its stakeholders.

The Company has entered into a Forbearance Agreement (the “Forbearance Agreement”) with Debenture holders representing 58% of the Debentures’ aggregate principal amount outstanding (the “Holders”). An ad hoc Steering Committee comprised of certain Debentureholders, and represented by Bennett Jones, has been established that will help facilitate ongoing negotiations surrounding the Convertible Debt. The Forbearance Agreement’s initial term extends to February 28, 2022, and the agreement automatically renews for 14-day periods thereafter unless notice to the contrary is provided (the “Term”).

Under the Forbearance Agreement, the Holders, among other considerations, forebear in enforcing their rights or remedies against the Company under the Indenture and otherwise at law with respect to the non-payment of interest until the expiry of the Term. The Company, in turn, has agreed to certain customary and standard covenants regarding carrying on business in the ordinary course during the Term.

Under the Forbearance Agreement, the Holders and the Company have agreed to work expeditiously and in good faith to negotiate a potential transaction to amend the terms associated with the Convertible Debt. There can be no assurance that the negotiations will result in a transaction.

For Investor & Media Relations:

1-833-879-2533

IR@AleafiaHealth.com 

LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The Company has developed an international footprint, with subsidiaries or investments in German and Australian medical cannabis companies and has products available in both markets. The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners who have seen over 75,000 patients to date.

Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the medical and adult-use markets, and in select international jurisdictions.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

FAQ

What is the Forbearance Agreement Aleafia Health entered into?

Aleafia Health entered into a Forbearance Agreement with holders of 58% of its convertible debentures to negotiate better debt terms.

What percentage of debenture holders agreed to the Forbearance Agreement?

The Forbearance Agreement was agreed upon by holders representing 58% of the total convertible debentures.

What is the term of the Forbearance Agreement for Aleafia Health?

The Forbearance Agreement initially extends until February 28, 2022, with automatic renewal for 14-day periods unless terminated.

What are the implications of the Forbearance Agreement for Aleafia Health investors?

The Forbearance Agreement allows Aleafia Health time to negotiate its debt situation, but it also highlights potential financial struggles.

What is the current status of Aleafia Health's convertible debt?

The convertible debt, issued on June 27, 2019, is set to mature on June 27, 2022, and the company is negotiating amendments.